全文获取类型
收费全文 | 20749篇 |
免费 | 5931篇 |
国内免费 | 126篇 |
专业分类
耳鼻咽喉 | 625篇 |
儿科学 | 616篇 |
妇产科学 | 690篇 |
基础医学 | 285篇 |
口腔科学 | 2643篇 |
临床医学 | 4135篇 |
内科学 | 5014篇 |
皮肤病学 | 454篇 |
神经病学 | 1795篇 |
特种医学 | 978篇 |
外科学 | 3749篇 |
综合类 | 54篇 |
现状与发展 | 12篇 |
预防医学 | 2681篇 |
眼科学 | 319篇 |
药学 | 182篇 |
中国医学 | 6篇 |
肿瘤学 | 2568篇 |
出版年
2024年 | 163篇 |
2023年 | 1089篇 |
2022年 | 353篇 |
2021年 | 627篇 |
2020年 | 1211篇 |
2019年 | 476篇 |
2018年 | 1319篇 |
2017年 | 1280篇 |
2016年 | 1497篇 |
2015年 | 1552篇 |
2014年 | 1950篇 |
2013年 | 2352篇 |
2012年 | 742篇 |
2011年 | 706篇 |
2010年 | 1342篇 |
2009年 | 1933篇 |
2008年 | 721篇 |
2007年 | 475篇 |
2006年 | 627篇 |
2005年 | 439篇 |
2004年 | 308篇 |
2003年 | 276篇 |
2002年 | 240篇 |
2001年 | 375篇 |
2000年 | 270篇 |
1999年 | 375篇 |
1998年 | 498篇 |
1997年 | 480篇 |
1996年 | 531篇 |
1995年 | 386篇 |
1994年 | 299篇 |
1993年 | 259篇 |
1992年 | 173篇 |
1991年 | 152篇 |
1990年 | 135篇 |
1989年 | 140篇 |
1988年 | 122篇 |
1987年 | 121篇 |
1986年 | 98篇 |
1985年 | 92篇 |
1984年 | 75篇 |
1983年 | 89篇 |
1982年 | 82篇 |
1981年 | 67篇 |
1980年 | 45篇 |
1979年 | 32篇 |
1978年 | 32篇 |
1977年 | 43篇 |
1976年 | 31篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
972.
973.
David S. Knopman MD Clifford R. Jack Jr MD Heather J. Wiste BA Stephen D. Weigand MS Prashanthi Vemuri PhD Val J. Lowe MD Kejal Kantarci MD Jeffrey L. Gunter PhD Matthew L. Senjem MS Michelle M. Mielke PhD Rosebud O. Roberts MBBCh Bradley F. Boeve MD Ronald C. Petersen MD PhD 《Annals of neurology》2013,73(4):472-480
974.
975.
976.
977.
978.
Patrick Smith Ph.D. Martti T. Tuomisto Ph.D. James Blumenthal Ph.D. Andrew Sherwood Ph.D. Lauri Parkkinen MS Mika Kähönen MD Ilkka Pörsti MD Silja Majahalme MD Väinö Turjanmaa MD 《Annals of behavioral medicine》2013,45(1):99-109
Background
Psychosocial factors have been associated with cardiovascular outcomes, but few studies have examined the association between psychosocial function and natriuretic peptides.Purpose
The purpose of this study is to determine the predictive value of hostility, anger, and social support in relation to atrial natriuretic peptide (ANP), a marker of vascular health, among middle-aged men.Methods
One hundred twenty-one men (mean age?=?39.8 years, SD?=?4.1) underwent assessments of ANP and completed the Cook–Medley Hostility Scale, the Spielberger State–Trait Anger Scale, and the Interview Schedule for Social Interaction.Results
Higher levels of hostility (β?=?0.22 [95 % CI 0.04, 0.40], P?=?0.032) and trait anger (β?=?0.18 [95 % CI 0.01, 0.37], P?=?0.044) were associated with greater ANP levels. In contrast, higher perceived social support was also associated with lower ANP levels, (β?=??0.19 [95 % CI ?0.05, ?0.41], P?=?0.010).Conclusions
Psychosocial factors, including hostility, anger, and social support, are associated with varying ANP levels among middle-aged men, independent of cardiovascular and behavioral risk factors. 相似文献979.
Raja Mehanna MD Christine Hunter RN Anthony Davidson MS Joohi Jimenez‐Shahed MD Joseph Jankovic MD 《Movement disorders》2013,28(2):210-215
Tetrabenazine is effective in the treatment of the chorea associated with Huntington disease and other hyperkinetic movement disorders. Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are CYP2D6 substrates. There are 4 CYP2D6 genotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultrarapid metabolizers. CYP2D6 genotyping was performed on sequential subjects treated with tetrabenazine, but results were not known at the time of titration. Duration of titration to a stable dose, total daily dose, response rating scores, and adverse events were retrospectively collected and subsequently analyzed. Of 127 patients, the majority (n = 100) were categorized as extensive metabolizers, 14 as intermediate metabolizers, 11 as poor metabolizers, and 2 as ultrarapid metabolizers. Ultrarapid metabolizer patients needed a longer titration (8 vs 3.3, 4.4, and 3 weeks, respectively; P < .01) to achieve optimal benefit and required a higher average daily dose than the other patients, but this difference did not reach statistical significance. The treatment response was less robust in the intermediate metabolizer group when compared with the extensive metabolizer patients (P = .013), but there were no statistically significant differences between the various groups with regard to adverse effects. Our findings demonstrate that, aside from the need for a longer titration in the ultrarapid metabolizers, there are no distinguishing features of patients with various CYP2D6 genotypes, and therefore the current recommendation to systematically genotype all patients prescribed more than 50 mg/day of tetrabenazine should be reconsidered. © 2012 Movement Disorder Society 相似文献
980.